Готові списки джерел за темами / Myocardial revascularization

Зміст

  1. Статті в журналах
  2. Дисертації
  3. Книги
  4. Частини книг
  5. Тези доповідей конференцій
  6. Звіти організацій

Добірка наукової літератури з теми "Myocardial revascularization"

Автор: Grafiati
Опубліковано: 4 червня 2021
Оновлено: 26 липня 2024

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Myocardial revascularization".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Myocardial revascularization"

1

Vasiliev, D. K., B. A. Rudenko, A. S. Shanoyan, F. B. Shukurov, and D. A. Feshchenko. "Endovascular myocardial revascularization in patients with multivessel coronary artery disease with chronic total occlusion and high surgical risk." Cardiovascular Therapy and Prevention 19, no. 6 (December 31, 2020): 2697. http://dx.doi.org/10.15829/1728-8800-2020-2697.

Повний текст джерела
Анотація:
The main reason for incomplete myocardial revascularization is the presence of chronic coronary total occlusion (CTO), which is detected in every fourth patient during coronary angiography. At the same time, a generally accepted approach to the treatment of CTO has not yet been developed.Aim. To assess the rationale of complete myocardial revascularization in patients with multivessel coronary artery disease (CAD) with chronic total occlusion and high surgical risk.Material and methods. This retrospective, open-label, non-randomized clinical trial was carried out included 180 patients multivessel CAD and CTO. The patients underwent endovascular surgery for complete myocardial revascularization. Depending on the success of surgery, the patients were divided into groups of complete and incomplete myocardial revascularization. Endpoints were death, acute coronary syndrome, re-revascularization after 1-year follow-up. Left ventricular (LV) contractility and clinical status of patients in the study groups after 1 year of observation was assessed.Results. The median follow-up was 12,1 months. The successful rate of revascularization was 79,4%. The incidence of main composite endpoint in the group of complete myocardial revascularization was 5,59%, while in the group of incomplete revascularizations — 21,6% (p=0,005).Conclusion. The study showed that low incidence of intraoperative complications and a high successful rate of revascularization are characteristic of complete myocardial revascularization in patients at high surgical risk with multivessel CAD and CTO. Complete myocardial revascularization leads to a significant decrease in the incidence of major coronary events.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Baran, I., B. Ozdemir, S. Gullulu, AA Kaderli, T. Senturk, and A. Aydinlar. "Prognostic Value of Viable Myocardium in Patients with Non-Q-wave and Q-wave Myocardial Infarction." Journal of International Medical Research 33, no. 5 (September 2005): 574–82. http://dx.doi.org/10.1177/147323000503300513.

Повний текст джерела
Анотація:
This study assessed the amount and prognostic value of myocardial viability in patients with non-Q-wave myocardial infarction (NQMI) and Q-wave myocardial infarction (QMI). A total of 175 patients with MI and an ejection fraction ≤ 45% underwent dobutamine stress echocardiography. On the basis of clinical criteria and myocardial viability, 110 patients were revascularized. The amount of viable myocardium and the clinical outcome were compared in the NQMI and QMI groups. Patients with NQMI exhibited a larger amount of viable myocardium compared with those with QMI. The mortality rate was 6% in patients with NQMI with viable myocardium and subsequent revascularization, 33% in patients with NQMI without viable myocardium or revascularization, 27% in patients with QMI with viable myocardium and subsequent revascularization, and 33% in patients with QMI without viable myocardium or revascularization. In conclusion, our data suggest that patients with NQMI and viable myocardium have the best prognosis after revascularization.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Shevchenko, Yury. "Scintigraphy after Various Methods of Myocardial Revascularization." Cardiology Research and Reports 2, no. 2 (October 13, 2020): 01–06. http://dx.doi.org/10.31579/2692-9759/007.

Повний текст джерела
Анотація:
Abstract. This article presents a comprehensive assessment of the perfusion-functional state of the LV myocardium after direct and indirect revascularization methods at various times after surgery to evaluate the complex relationship between myocardial viability and the method of revascularization. The research shows a significant advantage to using the YurLeon method of inducing extracardial revascularization of the myocardium in patients with diffuse coronary lesions. Aim. Comparative dynamic of scintigraphic indicators with various methods of revascularization. Materials and Methods.The study included 214 patients who underwent myocardial revascularization in various ways. Gated-SPECT was performed before the operation, as well as 1 month, 6 months, 1 year, and 2 or more years after the operation. Results.The groups of patients after CABG and CABG+YurLeon had differences in SRS indicators one year after surgery: 6.58±7.37 (after CABG) and 1.01±1.49 (CABG+YurLeon)(p<0.05).The most significant changes in systolic thickening (WT) occurred in segments with an accumulation of 26-40%: 1.78±1.84 (CABG), 0.51±0.85 (CABG+YurLeon), 2.6±1.19(PCI); and in segments 41-50%: 1.23±1.10 (CABG), 0.14±0.39 (CABG+YurLeon), 2.1±0.8 (PCI) (p<0.05).In the long-term period after revascularization, the total percentage of LV myocardial segments with "functional-perfusion mismatch" stood at: 11.08±11.69% of segments (CABG), 1.26±2.7% (CABG+YurLeon), 18.44±8.70% (PCI) (p<0.05). Conclusion. Comprehensive diagnostics of patients before surgery, including gated-SPECT, allow medical professionals to more effectively choose the method of revascularization and predict the nearest and separated results. Coronary bypass surgery together with the YurLeon technique of indirect myocardial revascularization in patients with severe diffuse lesions of the coronary artery shows more effective results than other methods of surgically treating IHD.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Mohamed, Salah. "Myocardial Revascularization." Sudan Heart Journal 6, no. 2 (January 1, 2019): 19–20. http://dx.doi.org/10.25239/shj/vol6/no2/commentary.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

RAJAN, RS. "MYOCARDIAL REVASCULARIZATION." Medical Journal Armed Forces India 51, no. 3 (July 1995): 194–201. http://dx.doi.org/10.1016/s0377-1237(17)30965-6.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Whittaker, Peter. "Myocardial revascularization." Annals of Thoracic Surgery 61, no. 6 (June 1996): 1874–75. http://dx.doi.org/10.1016/0003-4975(96)80211-6.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Babes, Elena Emilia, Delia Mirela Tit, Alexa Florina Bungau, Cristiana Bustea, Marius Rus, Simona Gabriela Bungau, and Victor Vlad Babes. "Myocardial Viability Testing in the Management of Ischemic Heart Failure." Life 12, no. 11 (November 1, 2022): 1760. http://dx.doi.org/10.3390/life12111760.

Повний текст джерела
Анотація:
Although major advances have occurred lately in medical therapy, ischemic heart failure remains an important cause of death and disability. Viable myocardium represents a cause of reversible ischemic left ventricular dysfunction. Coronary revascularization may improve left ventricular function and prognosis in patients with viable myocardium. Although patients with impaired left ventricular function and multi-vessel coronary artery disease benefit the most from revascularization, they are at high risk of complications related to revascularization procedure. An important element in selecting the patients for myocardial revascularization is the presence of the viable myocardium. Multiple imaging modalities can assess myocardial viability and predict functional improvement after revascularization, with dobutamine stress echocardiography, nuclear imaging tests and magnetic resonance imaging being the most frequently used. However, the role of myocardial viability testing in the management of patients with ischemic heart failure is still controversial due to the failure of randomized controlled trials of revascularization to reveal clear benefits of viability testing. This review summarizes the current knowledge regarding the concept of viable myocardium, depicts the role and tools for viability testing, discusses the research involving this topic and the controversies related to the utility of myocardial viability testing and provides a patient-centered approach for clinical practice.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Shilov, A. A., N. A. Kochergin, V. I. Ganyukov, A. N. Kokov, K. A. Kozyrin, A. A. Korotkevich, and O. L. Barbarash. "Comparability of scintigraphy data with coronary angiography after surgical myocardial revascularization." Regional blood circulation and microcirculation 18, no. 3 (October 7, 2019): 23–28. http://dx.doi.org/10.24884/1682-6655-2019-18-3-23-28.

Повний текст джерела
Анотація:
Introduction. Radionuclide imaging is included in diagnostic methods after PCI and CABG in patients with symptoms, but the recommendations caution against routine testing in all asymptomatic patients after revascularization. The paper shows the results of single-photon emission computed tomography after hybrid coronary myocardial revascularization; an analysis of the sensitivity and specificity of three methods of surgical myocardial revascularization was carried out in 12 months.Aim of the study was to determine the sensitivity and specificity of SPECT in determining coronary artery stenosis ≥ 50 % after performing three methods of surgical myocardial revascularization: CABG, PCI, and hybrid myocardial revascularization in patients with coronary artery disease and multi-vascular coronary lesion.Material and methods. A retrospective analysis of 82 patients with stable forms of coronary artery disease who underwent myocardial revascularization for the presence of the multivascular coronary lesion was carried out. The patients were divided into three groups: the first group consisted of 40 patients who underwent CABG, the second – 29 patients after PCI, and the third – 23 patients who underwent hybrid myocardial revascularization.Results. All patients after myocardial revascularization, on average, after 21.8±8.6 months, were hospitalized, where singlephoton emission computed tomography of the myocardium with 99mTc-technetril (SPECT) and control coronarography/ shuntography were performed. The frequency of the presence of significant stenosis during coronary angiography with a perfusion defect of ≥5 % on SPECT during exercise was 50, 50 and 33 % in the CABG, PCI, and hybrid revascularization, respectively (p=0.894). The least sensitivity of SPECT was after hybrid myocardial revascularization (20 %), while in the CABG group, the sensitivity was 71.4 % (p = 0.190). The SPECT specificity indices were much higher: in the GABG, PCI, and hybrid revascularization groups, respectively, 75.8, 79 and 88.9 % (p=0.530).Conclusion. There is no significant relationship between the size of the defect on SPECT and coronary angiography data, regardless of the type of surgical myocardial revascularization in patients after myocardial revascularization. Detection of a perfusion defect with a load of more than 10% in SPECT after surgical myocardial revascularization is the basis for coronary angiography in order to exclude stent restenosis or shunt dysfunction, as well as progression of coronary atherosclerosis.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Bolognese, Leonardo, and Matteo Rocco Reccia. "Myocardial viability on trial." European Heart Journal Supplements 26, Supplement_1 (April 2024): i15—i18. http://dx.doi.org/10.1093/eurheartjsupp/suae005.

Повний текст джерела
Анотація:
Abstract The concept of myocardial viability is usually referred to areas of the myocardium, which show contractile dysfunction at rest and in which contractility is expected to improve after revascularization. The traditional paradigm states that an improvement in function after revascularization leads to improved health outcomes and that assessment of myocardial viability in patients with ischaemic left ventricular dysfunction (ILVD) is a prerequisite for clinical decisions regarding treatment. A range of retrospective observational studies supported this ‘viability hypothesis’. However, data from prospective trials have diverged from earlier retrospective studies and challenge this hypothesis. Traditional binary viability assessment may oversimplify ILVD’s complexity and the nuances of revascularization benefits. A conceptual shift from the traditional paradigm centred on the assessment of viability as a dichotomous variable to a more comprehensive approach encompassing a thorough understanding of ILVD’s complex pathophysiology and the salutary effect of revascularization in the prevention of myocardial infarction and ventricular arrhythmias is required.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Kovárník, Tomáš, Štěpán Jeřábek, and Petr Kala. "Functional myocardial revascularization." Intervenční a akutní kardiologie 19, no. 1 (June 1, 2020): 39–46. http://dx.doi.org/10.36290/kar.2020.017.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "Myocardial revascularization"

1

Khoury, Vincent K. "Beyond revascularisation and recovery of regional ventricular function : implications of myocardial viability for medical treatment and remodelling /." [St. Luica, Qld.], 2002. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe16861.pdf.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Benhameid, Osama Saleh. "Myocardial revascularization using Omentum graft "Old wine in a new bottle"." Thesis, McGill University, 2004. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=81267.

Повний текст джерела
Анотація:
Background. Therapeutic angiogenesis in cardiovascular disease aims at improving myocardial function by increasing blood flow to ischemic myocardium that is not amenable to traditional forms of revascularization. This study hypothesizes that using the Omental graft to wrap the ischemic heart will lead to formation of multiple collateral anastomoses between surrounding systemic arteries and the coronary arteriolar system of right and left coronary arteries.
Results. Left ventricular end diastolic pressure was reduced in the group treated with revascularized Omental graft compared to vehicle group. Ejection fraction was also improved in revascularized group then infarcted group. Measurements of the myocardial infarction area showed more reduction in the MI area of the revascularized group than in the vehicle group, however this difference did not reach statistical significances. In comparison between free and pedicle Omental grafts, the free Omentum was shown to be superior over the pedicle in terms of cardiac function EF% (41.3 +/- 0.75 Vs. 35.6 +/- 0.75, P = 0.01), and infarction size (36.2 +/- 6.6 Vs. 39.5 +/- 13, P = NS). All different Omental grafts showed the ability to form a neovascularization between the ischemic myocardium and the surrounding structures.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Jones, Tina. "Interventional cardiology: a portfolio of research pertaining to femoral sheath removal practices and patient education." Title page, table of contents and portfolio structure and overview only, 2003. http://web4.library.adelaide.edu.au/theses/09DNS/09dnsj798.pdf.

Повний текст джерела
Анотація:
"March 2003" Includes bibliographical references (leaves 61-68). Appendices: Publications arising from the research portfolio. 1. Conducting a systematic review -- 2. The effectiveness of mechanical compression devices in attaining hemostasis after removal of a femoral sheath following femoral artery cannulation for cardiac interventional procedures : a systematic review -- 3. Effectiveness of mechanical compression devices in attaining hemostasis after femoral sheath removal Contains three separate research projects, presented as separate reports, but all related to one area of interest - interventional cardiology. Seeks to identify effective femoral sheath removal practices after interventional cardiac procedures and determine patient's perceptions of the education prior to and after interventional procedures.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

STEFANINI, GIULIO GIUSEPPE. "Myocardial revascularization with drug-eluting coronary artery stents: the clinical impact of technological progress." Doctoral thesis, Università degli Studi di Roma "Tor Vergata", 2013. http://hdl.handle.net/2108/211062.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Rubilis, Aigars. "T-vector and T-loop morphology analysis of ventricular repolarization in ischemic heart diseases /." Stockholm : Karolinska institutet, 2007. http://diss.kib.ki.se/2007/978-91-7357-443-3/.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Stenestrand, Ulf. "Improving outcome in acute myocardial infarction : the creation and utilisation of the Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA) /." Linköping : Univ, 2002. http://www.bibl.liu.se/liupubl/disp/disp2002/med740s.pdf.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Lindholm, Daniel. "Platelet Inhibition, Revascularization, and Risk Prediction in Non-ST-elevation Acute Coronary Syndromes." Doctoral thesis, Uppsala universitet, Kardiologi, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-265083.

Повний текст джерела
Анотація:
Cardiovascular disease is the leading cause of death worldwide and ischemic heart disease is the most common manifestation. Despite improved outcomes during the last decades, patients with acute coronary syndromes (ACS) are still at substantial risk of recurrent ischemic events and mortality. The aims of this thesis were to investigate the effect of the novel antiplatelet agent ticagrelor versus clopidogrel in patients with non-ST-elevation ACS (NSTE-ACS), overall and in relation to initial revascularization, and to explore this effect in relation to cardiac biomarkers. The impact of timing of revascularization in non-ST-elevation myocardial infarction (NSTEMI) was also studied, by assessing risk of mortality and recurrent myocardial infarction in relation to delay of percutaneous coronary intervention (PCI) in a nation-wide cohort. Finally, a novel clinical prediction model based on angiographic findings, biomarkers, and clinical characteristics was developed to estimate risk of ischemic events after performed revascularization. Ticagrelor treatment compared with clopidogrel was associated with a reduction in the composite endpoint of cardiovascular death/myocardial infarction/stroke and mortality alone, without any increase in overall major bleeding, but increased non-CABG-related major bleeding. The effect of ticagrelor over clopidogrel was consistent independent of initial revascularization. Elevated high-sensitivity cardiac troponin-T predicted benefit of ticagrelor over clopidogrel, while no difference between treatments was detected at normal levels. In patients with NSTEMI, PCI treatment within two days after hospital admission was associated with lower risk of all-cause death and recurrent myocardial infarction compared with delayed PCI. The new clinical prediction model included the following variables: prior vascular disease, extent of coronary artery disease, level of N-terminal pro-B-type natriuretic peptide and estimated glomerular filtration rate; and showed good discriminatory ability for the risk prediction of cardiovascular death/myocardial infarction/stroke and cardiovascular death alone. In conclusion, these results show that ticagrelor reduces the risk of recurrent ischemic events and mortality in patients with NSTE-ACS when compared with clopidogrel, and this effect seems independent of performed revascularization. The results also indicate that biomarkers could be used to select patients who would benefit most from more intense platelet inhibition. Furthermore, early PCI in NSTEMI seems to be associated with improved outcome. Finally, the novel clinical prediction model based only on four variables showed good discriminatory ability, which makes it a potentially effective and simple tool for tailored treatment based on individual risk of recurrent events.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Baptista, Vanessa Cristina 1982. "Correlação do teste de caminhada de seis minutos e EuroSCORE com a qualidade de vida em pacientes submetidos à revascularização do miocárdio." [s.n.], 2012. http://repositorio.unicamp.br/jspui/handle/REPOSIP/311524.

Повний текст джерела
Анотація:
Orientador: Orlando Petrucci Júnior
Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas
Made available in DSpace on 2018-08-19T17:01:26Z (GMT). No. of bitstreams: 1 Baptista_VanessaCristina_M.pdf: 1454154 bytes, checksum: dc039f58961bfe31946dfa04724885d1 (MD5) Previous issue date: 2012
Resumo: Introdução: A qualidade de vida após a revascularização do miocárdio não é frequentemente avaliada. Formas de estimar a qualidade de vida após a operação são úteis para prognóstico e discussão com o paciente sobre as opções disponíveis de tratamento. Objetivo: Avaliar a utilidade do teste de caminhada de seis minutos e do EuroSCORE como indicadores prognóstico de qualidade de vida em pacientes submetidos à revascularização do miocárdico. Material e Método: Estudo prospectivo observacional em pacientes submetidos à operação de revascularização do miocárdio. Foram avaliados as características clínicas, o índice EuroSCORE, teste de caminha de seis minutos e questionário para avaliação de qualidade de vida o questionário SF-36. No período pré-operatório os pacientes foram avaliados e divididos em dois grupos conforme a distância percorrida no teste de caminhada: grupo A (caminhou mais de 350 metros) e grupo B (caminhou menos de 350 metros). Resultados: Foram incluídos no estudo 87 pacientes, com idade média semelhante no grupo A comparado ao B (59 ± 9,5 anos vs. 61 ± 9,3 anos; P= 0,24) o mesmo foi observado para o EuroSCORE (2 ± 1 % vs. 3 ± 3%; P= 019). Os pacientes do grupo A caminharam mais no teste de 6 minutos após dois meses de operação (436 ± 78 m vs. 348 ± 87m; P<0,01) quando comparado ao grupo B. Observamos que a qualidade de vida era inferior no grupo B em relação ao grupo A no período pré-operatório nos domínios: capacidade funcional, aspectos físicos, estado geral de saúde, vitalidade e aspectos sociais. A qualidade de vida melhorou após dois meses em ambos os grupos. Conclusões: O teste de caminhada de 6 minutos no pré-operatório tem correlação com a qualidade de vida após dois meses de operação de revascularização do miocárdio. O EuroSCORE não tem correlação com a qualidade de vida após dois meses de operação. A qualidade de vida melhorou de forma geral em todos pacientes, sendo maior a melhora da qualidade de vida naqueles que caminharam menos que 350 metros no pré-operatório
Abstract: Introduction: The quality of life after coronary artery bypass surgery (CABG) is not often assessed in the literature. Tools for quality of life assessment are useful for analysis of long-term results, and it is effective for a conference with the clinical team and family's patient. Objective: Assess the quality of life in patients undergoing myocardial revascularization using the six-minute walk test and the EuroSCORE index. Material and Method: Prospective observational study with patients who undergoing CABG. The clinical variables, the EuroSCORE index, the six-minute walk test, and the SF-36 test were recorded. The patients were assessed at preoperative time and at 2 months of postoperative period. According their six-minute walk test results, the patients were divided into two groups: group A (walked more than 350 meters) and group B (walked less than 350 meters) at the preoperative time. Results: Eight-seven patients were included. Age and EuroSCORE index was comparable in both groups (59 ± 9.5 years vs. 61 ± 9.3 years; P = 0.24) and (2 ± 1%vs. 3. ± 3%; P = 019), respectively. The group A walked distance was higher than the group B after 2 months of operation (436 ± 78 m vs. 348 ± 87 m; P <0.01). The quality of life was lower in the group B compared to the group A at the preoperative period in the following domains: functional capabilities, limitations due to physical aspects, overall health feelings, vitality, and social aspects. Quality of life improved after two months in both groups. Conclusions: The six-minute walk test at the preoperative time is associated with the quality of life after two months of CABG. The EuroSCORE has not correlation with the quality of life after two months of operation. In overall, quality of life has improved in all patients. The improvement in the quality of life was greater in those patients who walked distances lower than 350 meters at the preoperative time
Mestrado
Fisiopatologia Cirúrgica
Mestre em Ciências
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Barbosa, Ricardo Antonio Guimarães. "Avaliação farmacocinética e farmacodinâmica do propofol em pacientes submetidos à revascularização do miocárdio, com ou sem utilização de circulação extracorpórea." Universidade de São Paulo, 2004. http://www.teses.usp.br/teses/disponiveis/5/5152/tde-13102014-113751/.

Повний текст джерела
Анотація:
A circulação extracorpórea (CEC) pode alterar a concentração plasmática prevista para fármacos administrados durante a anestesia. Os objetivos deste estudo foram avaliar os efeitos da CEC sobre a farmacocinética, farmacodinâmica e as concentrações plasmáticas do propofol em pacientes submetidos à cirurgia de revascularização miocárdica (RM) com ou sem utilização de CEC, correlacionando-se às concentrações plasmáticas obtidas com as previstas por infusão contínua alvo-controlada. Dez pacientes submetidos à RM com CEC (Grupo CEC) e dez sem CEC (Grupo sem CEC) foram comparados em relação à concentração plasmática obtida, utilizando-se cromatografia líquida de alta eficiência e aquela prevista por infusão alvo-controlada, em relação à farmacocinética (t1/2ß, volume de distribuição e clearance plasmático), ao grau de hipnose (índice bispectral) e aos parâmetros hemodinâmicos (pressão arterial média e freqüência cardíaca), avaliados nos períodos intra-operatório e pós-operatório imediato. Os dados foram avaliados pela análise de variância para medidas repetidas, considerando-se significativo p<0,05. A concentração obtida de propofol foi maior no grupo sem CEC nos momentos 120 min (3,32±1,76 no grupo sem CEC e 2,48±1,12 no grupo CEC, p=0,005) e 240 min (3,24±2,71 no grupo sem CEC e 2,23±2,48 no grupo CEC, p=0,0212) após o início da cirurgia. A concentração medida de propofol foi maior que a prevista nos 2 grupos, com valores superiores no grupo sem CEC (p=0,02). O t1/2 ß foi maior no grupo sem CEC (3,67±1,15 grupo sem CEC e 1,82±0,5 no grupo CEC, p=0,0005) e o clearance plasmático maior no grupo CEC (28,36±11,40 no grupo CEC e 18,29±7,67 no grupo sem CEC, p=0,03). O grau de hipnose foi superior no grupo CEC. Os grupos não diferiram quanto à análise hemodinâmica. Conclui-se que a CEC promove alterações na farmacocinética e nas concentrações plasmáticas de propofol, com conseqüente diferença no grau de hipnose em relação aos pacientes submetidos à revascularização do miocárdio sem utilização de CEC
Cardiopulmonary bypass (CPB) can alter predicted plasmatic concentration of drugs administered during anesthesia. The aim of this study was evaluate the effects of cardiopulmonary bypass under pharmacokinetics, pharmacodynamics and plasmatic concentration of propofol in patients undergoing coronary artery bypass grafting surgery (CABG) with or without CPB, comparing measured plasmatic concentration with predicted concentration administered by target-controlled infusion. Ten patients undergoing coronary artery bypass grafting surgery with CPB (CPB Group, n=10) and ten without CPB (off-pump Group, n=10) were compared in relaction to measured plasmatic concentration using high performance liquid chromatography (HPLC) and predicted concentration administered by target-controlled infusion, pharmacokinetics (t1/2 ß, volume of distribution and total clearance), hypnosis degree (bispectral index) and hemodynamics parameters (mean arterial pressure and heart rate) during and after surgery. Statistical analysis was done using analysis of variance for repeated measures (*p<0,05). Measured plasmatic concentration was higher in off-pump group in the moments 120 min (3,32±1,76 in off-pump group and 2,48±1,12 in CPB group, p=0,005) and 240 min (3,24±2,71 in off-pump group and 2,23±2,48 in CPB group, p=0,0212) after the beginning of surgery. Measured plasmatic concentration was higher than predicted in two groups, with superior values in off-pump group (p=0,02). T1/2 ß was greater in off-pump group (3,67±1,15 in off-pump group and 1,82±0,5 in CPB group, p=0,0005) and total clearance was higher in CPB group (28,36±11,40 in CPB group and 18,29±7,67 in off-pump group, p=0,03). Hypnosis degree was greater in CPB group. Hemodynamics parameters did not differ between the groups. In conclusion, CPB causes alterations on pharmacokinetics and under propofol plasmatic concentration with higher hypnosis degree when compared with patients undergoing coronary artery bypass grafting surgery without CPB (off-pump group)
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Lima, Francisca ElisÃngela Teixeira. "Protocolo de consultas de enfermagem ao paciente apÃs revascularizaÃÃo do miocÃrdio: avaliaÃÃo da eficÃcia." Universidade Federal do CearÃ, 2007. http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=1053.

Повний текст джерела
Анотація:
CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel Superior
O acompanhamento ao paciente submetido à cirurgia de revascularizaÃÃo do miocÃrdio (RM) deve ter uma abordagem holÃstica, realizado por uma equipe multiprofissional. Este estudo teve como objetivo geral avaliar um Protocolo de Consultas de Enfermagem (PCE) ao paciente apÃs RM, comparando com um grupo controle. E, como especÃficos: levantar caracterÃsticas dos pacientes em relaÃÃo a sexo, idade, escolaridade, renda familiar, estado civil, histÃria familiar de doenÃa arterial coronariana (DAC) e religiÃo; verificar prevalÃncia dos fatores de risco para DAC: hipertensÃo arterial, diabetes mellitus, dislipidemia, obesidade, sedentarismo e tabagismo; identificar mudanÃas comportamentais dos pacientes, enfatizando hÃbitos alimentares, exercÃcio fÃsico, abstinÃncia de tabagismo e etilismo, e uso contÃnuo de medicamentos; averiguar impacto do PCE na reduÃÃo dos fatores de risco para DAC, considerando o controle: pressÃo arterial, glicemia, colesterol, Ãndice de massa corporal, circunferÃncia da cintura e relaÃÃo cintura/quadril; e verificar aspectos relacionados à ansiedade e depressÃo. Ensaio clÃnico randomizado, desenvolvido no ambulatÃrio de um hospital pÃblico, Fortaleza-CE. Compuseram a populaÃÃo 146 pacientes revascularizados no perÃodo de coleta de dados, constituindo a amostra 78 pacientes, 39 do grupo controle (GC) e 39 do grupo de intervenÃÃo (GI). A participaÃÃo nos grupos foi definida pelo dia de cirurgia. Pacientes do GC fizeram o seguimento ambulatorial convencional, com avaliaÃÃo pela pesquisadora no momento da alta e seis meses apÃs a cirurgia; e pacientes do GI foram submetidos ao PCE com atendimentos na alta hospitalar e apÃs um, dois, quatro e seis meses. Estudo aprovado pelo Comità de Ãtica e Pesquisa. Encontrou-se similaridade nos grupos para os indicadores: sexo masculino (62,8%); idade (mÃdia: 65 anos); baixa escolaridade; renda familiar atà um salÃrio mÃnimo (55,1%); antecedentes familiares com DAC (65,4%); catÃlicos (82,1%). O estado civil apresentou diferenÃa significativa. Contudo, os fatores de risco para DAC nÃo apresentaram diferenÃas significativas (p>0,05): hipertensÃo arterial (83,3%), nÃo-diabÃticos (53,8%), sem dislipidemia (53,8%), obesidade (67,9%), sedentarismo (57,7%) e nÃo-tabagistas (65,4%). Na avaliaÃÃo da eficÃcia do PCE, os testes evidenciaram que 92,3%-GI e 76,9%-GC melhoraram a qualidade da alimentaÃÃo. O GI teve uma maior adesÃo à pratica de exercÃcio fÃsico do que o GC (p<0,10). Todos os pacientes do GI abstiveram-se do cigarro e do etilismo, e 33,3% dos fumantes e 50,0% dos usuÃrios de bebidas alcoÃlicas do GC mantiveram esses hÃbitos, constatando diferenÃa significativa (p<0,05). Um percentual maior (94,9%) do GI usava os medicamentos adequadamente (p>0,05). Houve um impacto na reduÃÃo dos fatores de risco para DAC, apÃs seis meses da cirurgia, quanto aos indicadores (p<0,05): pressÃo arterial, taxa de glicemia, Ãndice de massa corporal, circunferÃncia da cintura e relaÃÃo cintura/quadril. Conforme constatado, o GI teve um percentual menor de pessoas com ansiedade e/ou depressÃo em relaÃÃo ao GC. Conclui-se que o seguimento pelo PCE foi eficaz para as mudanÃas comportamentais no estilo de vida dos pacientes revascularizados. Como observado, um maior nÃmero de pessoas do GI melhorou a qualidade da dieta, aderiu à prÃtica de exercÃcio fÃsico e parou de fumar e de ingerir bebidas alcoÃlicas. Tais mudanÃas comportamentais foram positivas para reduzir fatores de risco e, conseqÃentemente, minimizar complicaÃÃes cardiovasculares.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "Myocardial revascularization"

1

R, Utley Joe, ed. Myocardial revascularization bibliography. Spartanburg, S.C: Cardiothoracic Research and Education Foundation, 1989.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

von Segesser, Ludwig K. Arterial Grafting for Myocardial Revascularization. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-75709-9.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Laham, Roger J., and Donald S. Baim, eds. Angiogenesis and Direct Myocardial Revascularization. Totowa, NJ: Humana Press, 2005. http://dx.doi.org/10.1007/978-1-59259-934-9.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

D, Angelini Gianni, Bryan Alan J, and Dion Robert M. D, eds. Arterial conduits in myocardial revascularization. London: Arnold, 1996.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

S, Abela George, ed. Myocardial revascularization: Novel percutaneous approaches. New York: Wiley-Liss, 2002.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

J, Laham Roger, and Baim Donald S, eds. Angiogenesis and direct myocardial revascularization. Totowa, N.J: Humana Press, 2005.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

G, Reves J., and Society of Cardiovascular Anesthesiologists, eds. Acute revascularization of the infarcted heart. Orlando: Grune & Stratton, 1987.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Whittaker, Peter, and George S. Abela, eds. Direct Myocardial Revascularization: History, Methodology, Technology. Boston, MA: Springer US, 1999. http://dx.doi.org/10.1007/978-1-4615-5069-3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

1939-, Whittaker Peter A., and Abela George S, eds. Direct myocardial revascularization: History, methodology, technology. Boston: Kluwer, 1999.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

1935-, Epstein Stephen E., Kornowski Ran, and Leon Martin B, eds. Handbook of myocardial revascularization and angiogenesis. London: Martin Dunitz, 2000.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "Myocardial revascularization"

1

Ashes, Catherine, and Saul Judelman. "Myocardial Revascularization." In Cardiac Anesthesia and Postoperative Care in the 21st Century, 199–207. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-79721-8_15.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Cosgrove, Delos M., and Floyd D. Loop. "Reoperative myocardial revascularization." In Improvement of Myocardial Perfusion, 310–16. Dordrecht: Springer Netherlands, 1985. http://dx.doi.org/10.1007/978-94-009-5032-0_46.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Ferrarotto, Luigi, Alessio La Manna, and Corrado Tamburino. "Percutaneous Myocardial Revascularization." In Ischemic Heart Disease, 369–82. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-25879-4_20.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Dewood, Marcus A., J. Paul Shields, Ralph Berg, and Robert N. Notske. "Myocardial Revascularization with Acute Myocardial Infarction." In Therapeutics in Cardiology, 599–612. Dordrecht: Springer Netherlands, 1988. http://dx.doi.org/10.1007/978-94-009-1333-2_68.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

DeRose, Joseph J., and Robert K. Jarvik. "Device-Supported Myocardial Revascularization." In Minimally Invasive Cardiac Surgery, 155–64. Totowa, NJ: Humana Press, 1999. http://dx.doi.org/10.1007/978-1-4757-3036-4_13.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Chloroyiannis, Yiannis A., and Andreas G. Synetos. "Total Arterial Myocardial Revascularization." In Coronary Graft Failure, 27–40. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-26515-5_4.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Auler, J. O. C., L. A. Dallan, and S. Almeida De Oliveira. "Myocardial Revascularization with Laser." In Anaesthesia, Pain, Intensive Care and Emergency Medicine — A.P.I.C.E., 991–1006. Milano: Springer Milan, 2002. http://dx.doi.org/10.1007/978-88-470-2099-3_86.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Chiaramonti, Francesca. "Indications for Myocardial Revascularization." In Ischemic Heart Disease, 323–33. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-25879-4_17.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Concistrè, Giovanni, and Marco Solinas. "Minimally Invasive Myocardial Revascularization." In Ischemic Heart Disease, 459–66. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-25879-4_27.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Sanne, H. "Rehabilitative Care After Myocardial Revascularization." In Reperfusion and Revascularization in Acute Myocardial Infarction, 244–51. Berlin, Heidelberg: Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-83544-5_32.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Myocardial revascularization"

1

Yano, Osvaldo J., Mark R. Bielefeld, Valluvan Jeevanandam, Michael R. Treat, Charles C. Marboe, Henry M. Spotnitz, and Craig R. Smith. "Endocardial laser myocardial revascularization." In OE/LASE'93: Optics, Electro-Optics, & Laser Applications in Science& Engineering, edited by George S. Abela. SPIE, 1993. http://dx.doi.org/10.1117/12.146583.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Loschenov, Victor B., Alexander A. Stratonnikov, S. Y. Vasilchenko, Anna I. Volkova, Sergey S. Kharnas, and E. A. Sheptak. "Development of the myocardial photodynamic revascularization method." In SPIE Proceedings, edited by Ruikang K. Wang, Jeremy C. Hebden, Alexander V. Priezzhev, and Valery V. Tuchin. SPIE, 2004. http://dx.doi.org/10.1117/12.572051.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Vasilchenko, S. Yu, A. A. Stratonnikov, A. I. Volkova, V. B. Loschenov, E. A. Sheptak, and S. S. Kharnas. "Investigation of myocardial photodynamic revascularization method on ischemic rat myocardium model." In SPIE Proceedings, edited by Valery V. Tuchin. SPIE, 2006. http://dx.doi.org/10.1117/12.697420.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

de Medeiros Nacácio e Silva, Paula, Nafice Costa Araújo, Renata Ferreira Rosa, Rina Dalva Neubarth Giorgi, Renata Maria Monteiro Pinto, Lucas Victória de Oliveira Martins, Stan Richard Medeiros de Souza, Danielle Arraes Rubini, and Marina de Azevedo Martins. "MYOCARDIAL REVASCULARIZATION AFTER ACUTE MYOCARDIAL INFARCTION BY THROMBOSED CORONARY ANEURYSM IN BEHÇET'S SYNDROME." In Congresso Brasileiro de Reumatologia 2020. Sociedade Brasileira de Reumatologia, 2021. http://dx.doi.org/10.47660/cbr.2020.17383.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Whittaker, Peter, Shi-Ming Zheng, and Robert A. Kloner. "Chronic response to direct myocardial revascularization: a preliminary study." In OE/LASE'93: Optics, Electro-Optics, & Laser Applications in Science& Engineering, edited by George S. Abela. SPIE, 1993. http://dx.doi.org/10.1117/12.146580.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Wu, Mingying, Gongsong Li, and Junheng Li. "Experimental study of myocardial revascularization by CO 2 laser." In International Conference on Photodynamic Therapy and Laser Medicine, edited by Junheng Li. SPIE, 1993. http://dx.doi.org/10.1117/12.137040.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Iakovleva, Maria, Nadezhda Kruglova, Olga Shchelkova, Ekaterina Lubinskaya, and Olga Nikolaeva. "POTENTIALS OF PSYCHOLOGICAL PREDICTION OF PATIENTS’ THERAPEUTIC BEHAVIOR AFTER MYOCARDIAL REVASCULARIZATION." In International Psychological Applications Conference and Trends. inScience Press, 2019. http://dx.doi.org/10.36315/2019inpact003.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Brendel, Tobias, Ralf Brinkmann, Dirk Theisen, and Reginald Birngruber. "Ablation Dynamics of High Energy IR Laser Pulses in Myocardial Revascularization." In Biomedical Topical Meeting. Washington, D.C.: OSA, 1999. http://dx.doi.org/10.1364/bio.1999.cwd4.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Grieshaber, P., M. Hamiko, M. Albert, J. Ginsberg, T. Krüger, F. Brenck, and A. Böning. "Surgical Myocardial Revascularization in Patients with Acute Myocardial Infarction and Cardiogenic Shock: Data from the GERMIN-SURG Registry." In 51st Annual Meeting of the German Society for Thoracic and Cardiovascular Surgery (DGTHG). Georg Thieme Verlag KG, 2022. http://dx.doi.org/10.1055/s-0042-1742882.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Hurley, Jennifer R., and Daria A. Narmoneva. "Fibroblasts Induce Mechanical Changes in the Extracellular Environment and Enhance Capillary-Like Network Formation." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-193093.

Повний текст джерела
Анотація:
Cardiac tissue engineering studies have demonstrated the importance of revascularization in engineered grafts for successful implantation and regeneration [1]. Understanding the myocardium’s complex cellular organization and the interactions between the major cardiac cell types (cardiomyocytes, endothelial cells, and cardiac fibroblasts) is critical for revascularization. Our previous studies have shown the importance of cardiomyocyte-endothelial interactions [2]. However, there is limited information available on endothelial-fibroblast interactions. We and others have previously observed that during capillary assembly, fibroblasts provide chemical signaling via expression of growth factors [3, 4]. In addition, fibroblasts may also regulate angiogenesis through alterations to the mechanical environment via myocardial remodeling, including matrix degradation and deposition, and tissue contraction. Changes to the extracellular mechanical enviroment may lead to changes in basic cell functions such as proliferation, apoptosis, and growth factor expression.
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Myocardial revascularization"

1

Li, Peng, Na jia, Bing Liu, and Qing He. Effect of cardiac shock wave therapy on adverse cardiovascular event for patients with coronary artery disease: an updated systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2022. http://dx.doi.org/10.37766/inplasy2022.1.0103.

Повний текст джерела
Анотація:
Review question / Objective: We have previously demonstrated that cardiac shock wave therapy (CSWT) effectively improves myocardial perfusion in patients with coronary artery disease (CAD). In this study, we want to address whether CSWT could decrease the risk of adverse cardiovascular events in CAD patients unsuitable for revascularization. Eligibility criteria: Trials are considered eligible if they meet these criteria: (1) patients included are diagnosed as refractory angina or ischemic heart failure; (2) the study i a randomized controlled trial (RCT) or a prospective cohort study; (3) intervention consisted of CSWT; (4) patients in the control group are treated with optimal medical therapy, (5)the primary outcome of interest Is rate of MACE. Exclusion criteria were (1) patients with acute myocardial infarction, (2) repeated CSWT, (3) with coronary artery revascularization, (4) without primary outcome, (5) retrospective study, and (6)duplicated data.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Krastev, Plamen. Dynamics of Left Ventricular Ejection Fraction under Revascularization of Patients with Acute Myocardial Infarction with ST-T Elevation and Single Coronary Artery Disease. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, 2021. http://dx.doi.org/10.7546/crabs.2021.05.16.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

McCausland, Rachel, Joann Fontanarosa, and Ravi Patel. Nonemergent Percutaneous Coronary Intervention Versus Optimal Medical Treatment for Stable Ischemic Heart Disease: A Rapid Response Literature Review. Agency for Healthcare Research and Quality (AHRQ), August 2023. http://dx.doi.org/10.23970/ahrqepcrapidcoronary.

Повний текст джерела
Анотація:
Aims. There is uncertainty around the optimal role of percutaneous coronary intervention (PCI) for management of chronic coronary syndrome, specifically when patients have disease in multiple coronary vessels and disease in the proximal portion of the left anterior descending coronary artery. This uncertainty was reflected in 2021 guidance from the American College of Cardiology (ACC)/American Heart Association (AHA) on coronary artery revascularization. The Agency for Healthcare Research and Quality has commissioned this rapid response literature review to meet a Congressional request for a summary of recent evidence on the benefits of angioplasties conducted in nonemergency situations. Methods. This rapid response literature review on the comparative effectiveness of nonemergent PCI followed established best systematic review methods, modified to meet a shortened project timeframe. We searched PubMed®, Embase®, and the Trip© medical database from 2018 through April 2023 for systematic reviews (SRs), clinical practice guidelines, and randomized controlled trials, and summarized the evidence comparing PCI to optimal medical therapy (OMT) for stable ischemic heart disease (SIHD). Our primary outcomes of interest were major objective cardiovascular outcomes, including mortality, myocardial infarction, stroke, urgent revascularization, or composites of one or more of these hard clinical outcomes. Where available, we also abstracted patient reported outcomes (e.g., angina severity and quality of life [QoL]) from included studies. Findings. Key findings from nine SRs and one primary study include: • The body of evidence directly comparing PCI to OMT for SIHD has remained largely unchanged since the 2021 ACC/AHA guidance’s publication. • Most studies of revascularization for coronary artery disease do not focus on direct head-to-head comparisons of PCI versus OMT for SIHD but instead either (1) compare OMT to invasive revascularization (PCI and coronary artery bypass graft [CABG] combined cohort); (2) compare PCI to CABG; or (3) compare different PCI techniques. • Another factor that complicates comparison is that the meta-analyses often included data from CABG and PCI combined cohorts (e.g., the recent landmark ISCHEMIA trial) but reported the outcomes as PCI specific. • In the general SIHD population, our review did not find evidence to support survival benefit or effect on hard clinical outcomes when PCI is added to OMT. • Limited evidence indicates there may be a beneficial effect of PCI on angina symptoms and measures of QoL, but most systematic reviews focused on major objective cardiovascular outcomes and did not consider QoL or freedom from angina. • Both OMT and PCI have evolved significantly during the period of time in which the systematic reviews’ included studies were conducted. It is not clear how these changes may have affected the applicability of past studies to current practice. Conclusions. The evidence directly comparing PCI to OMT for SIHD has remained largely unchanged since publication of the 2021 ACC/AHA guidelines. More research is needed to verify the comparative effectiveness of nonemergent PCI compared to medical treatment for individuals with SIHD, and how the effectiveness varies by certain patient populations and clinical presentation.
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "Myocardial revascularization" для конкретних типів джерел:
Статті в журналах Дисертації Книги
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії